montelukast and Colitis

The cysteinyl leukotrienes (CysLTs), i.e. LTC

Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bile Acids and Salts; Colitis; Cyclopropanes; Disease Models, Animal; Gene Expression; Genes, Reporter; HEK293 Cells; Hep G2 Cells; Humans; Leukotriene Antagonists; Leukotriene C4; Leukotriene D4; Leukotriene E4; Luciferases; Mice; Mice, Knockout; Molecular Docking Simulation; Quinolines; RAW 264.7 Cells; Receptors, G-Protein-Coupled; Receptors, Leukotriene; Recombinant Fusion Proteins; Sulfides

Cysteinyl leukotrienes play a part in inflammatory processes such as inflammatory bowel diseases. The present study aimed to evaluate the effects of the cys-LT-1 receptor antagonist montelukast on a mild colitis model in rats. Colitis was induced by administrating 4% dextran sulphate sodium (DSS, MW 45,000) in drinking water for 9 days. Montelukast (10 mg/kg/day) or vehicle was given by gastric gavage once daily simultaneously with DSS administration. A healthy control group receiving water as drinking fluid and vehicle by gastric gavage was included. Body weight loss, consistency of faeces (loose/diarrhoea) and occult blood in the faeces/ gross bleeding were assessed on days 6 - 9. After sacrifice, the following were assessed: colonic histology, the expression of inducible nitric oxide synthase, macrophage/monocyte marker ED1, cyclooxygenase-1 and cyclooxygenase-2, as well as the production of leukotriene B(4) and E(4), prostaglandin E(2), its metabolite bicyclic-prostaglandin E(2) and thromboxane B(2) in the colonic tissue incubation in vitro. Rats receiving DSS exhibited bloody diarrhoea from day 6 onwards. Montelukast significantly reduced the occult blood in the faeces/ gross bleeding, maintained normal body weight gain and tended to decrease the ratio of leukotriene B(4)/ prostaglandin E(2) production in the colon in vitro. The results indicate that montelukast has some potential to ameliorate mild experimental colitis induced by DSS.

Topics: Acetates; Administration, Oral; Animals; Blotting, Western; Body Weight; Bridged Bicyclo Compounds; Colitis; Colon; Cyclooxygenase 1; Cyclooxygenase 2; Cyclopropanes; Dextran Sulfate; Dinoprostone; Immunochemistry; Immunoglobulin G; Leukotriene Antagonists; Leukotriene B4; Male; Nitric Oxide Synthase Type II; Occult Blood; Quinolines; Rats; Rats, Wistar; Severity of Illness Index; Sulfides; Thromboxane B2

Cysteinyl leukotrienes play a part in inflammatory reactions such as inflammatory bowel diseases. The aim of the present study was to evaluate the acute effects of a cys-leukotriene-1 receptor antagonist, montelukast, on trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. Montelukast (5, 10 or 20 mg kg(-1) day(-1)), a 5-lipoxygenase inhibitor, zileuton (50 or 100 mg kg(-1) day(-1), a positive control), or the vehicle was administered intracolonically to the rats twice daily throughout the study, starting 12 h before the induction of colitis with TNBS. The severity of colitis (macroscopic and histological assessment, as well as myeloperoxidase activity), the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2, and eicosanoid production in colonic tissue incubation were assessed 24 and 72 h after colitis induction. Montelukast increased prostaglandin E(2) production at 24 h and tended to reduce the cyclooxygenase-2 protein expression at 72 h, but did not influence the severity of colitis. Zileuton failed to decrease the inflammatory reaction in spite of reduced leukotriene B(4) production at 72 h. The results suggest that drugs that block cysteinyl leukotriene receptors have limited potential to ameliorate acute TNBS-induced colitis, but that they exert some beneficial effects which make them capable of modulating the course of colitis.

Topics: Acetates; Animals; Colitis; Cyclooxygenase 2; Cyclopropanes; Isoenzymes; Leukotriene Antagonists; Leukotriene B4; Male; Membrane Proteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Prostaglandin-Endoperoxide Synthases; Quinolines; Rats; Rats, Wistar; Receptors, Leukotriene; Severity of Illness Index; Sulfides